A 16-week Mediterranean diet intervention significantly improves psoriasis severity in patients with mild-to-moderate disease receiving stable topical therapy.

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Guselkumab is the first IL-23 inhibitor approved for pediatric plaque psoriasis and active psoriatic arthritis, addressing a significant treatment gap. The PROTOSTAR study showed 56% of children on ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a ...

New findings from the POSITIVE trial demonstrate that tildrakizumab (Ilumya/Ilumetri) not only delivers strong skin clearance ...

Their condition often worsens when exposed to scorching sunlight or hot environments, leading patients to feel self-conscious ...

Researchers are uncovering how air pollution can trigger and worsen psoriasis, a chronic skin disease affecting millions ...

Patients with psoriasis were linked to greater risks for both exudative and nonexudative age-related macular degeneration.

A study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 found that individuals with ...

Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent ...